Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.36-1.07%BTC$77,099.00-0.87%ETH$2,266.70-0.70%GOLD$3,914.60-1.39%OIL$98.43+2.04%
Smart Investors Daily
SID Premium
Eloxx Pharmaceuticals, Inc. logo

OTC · ELOX

Eloxx Pharmaceuticals, Inc.

Healthcare · Biotechnology

$12.84

Down-$0.61 (-4.54%)

Updated Nov 3, 2026, 11:26 AM

SID Score

4.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
314
P/E ratio
-0
Dividend yield
0.00%
52-week range
$0.00 – $23.40
Volume
59.86K
Avg. volume
1.44K

Price performance · ELOX

ELOX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

ELOX closed at $12.84 after 21 trading sessions, down 16.68% for the selected period.

Last close
$12.84
Period change
-16.68%
Period low
$12.21
Period high
$15.41
Daily close
View OHLC price history
ELOX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$13.52$13.56$12.6001$12.8459.86K
Oct 30, 2026$12.98$13.78$12.98$13.4513.99K
Oct 29, 2026$13.78$13.78$12.50$13.2046.88K
Oct 28, 2026$13.19$13.99$12.79$13.1210.58K
Oct 27, 2026$13.10$13.34$12.4715$13.3410.47K
Oct 26, 2026$13.16$13.35$12.89$13.1726.67K
Oct 23, 2026$13.9979$13.9979$12.80$12.8027.61K
Oct 22, 2026$13.21$13.5552$12.64$13.1210.35K
Oct 21, 2026$13.34$13.565$12.725$13.3016.28K
Oct 20, 2026$12.86$13.77$12.86$13.2218.99K
Oct 19, 2026$13.06$14.24$12.49$12.5032.49K
Oct 16, 2026$13.95$14.15$12.85$13.0366.49K
Oct 15, 2026$12.24$14.24$12.00$13.7023.37K
Oct 14, 2026$13.13$13.2257$12.21$12.2112.55K
Oct 13, 2026$13.80$13.80$12.00$12.7021.81K
Oct 12, 2026$14.01$14.62$13.82$13.8926.09K
Oct 9, 2026$15.02$15.29$13.2101$13.7431.31K
Oct 8, 2026$14.67$15.505$14.67$15.1810.55K
Oct 7, 2026$15.27$15.72$14.72$14.8814.6K
Oct 6, 2026$15.34$16.02$14.50$15.1361.29K
Oct 5, 2026$15.25$16.81$15.25$15.4126.16K

Latest ELOX news

The latest Smart Investors Daily articles mentioning ELOX.

Stock researchCompany · Overview

ELOX research

Overview

Company profile and research snapshot.

Company profile

ELOXX PHARMACEUTICALS INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ELOX recent ratings
DateFirmRatingTarget
Oct 28, 2026GuggenheimBuy—
Oct 15, 2026Cantor FitzgeraldOverweight—
Sep 18, 2026Leerink PartnersOutperform—
Aug 24, 2026GuggenheimBuy—
Aug 20, 2026LUCID CAPITAL MARKETSBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 29, 2026

Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD

Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for exaluren for the treatment of nonsense-mutation autosomal dominant polycystic kidney disease (ADPKD). The IND clearance enables Eloxx to initiate EXPRESS, its global Phase 2 clinical trial, at clinical sites in t

Yahoo · Oct 20, 2026

Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical Officer

Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today announced the finalized design of its EXPRESS Phase 2 global study in nonsense-mutation autosomal dominant polycystic kidney disease (ADPKD) and the appointment of T.R. Srinivas, M.D., as Senior Vice President and Chief Medical Officer.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By